Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trialAna Oaknin, Juan Cueva, Munetaka Takekuma et al.|The Lancet|2023Cited by 225
Laboratory cross-comparison of tumor BRCA1/2 analysis in a multicenter epithelial ovarian cancer series: The BORNEO GEICO60-0 study.Ignacio Romero, Ana Vivancos, Ana Oaknin et al.|Journal of Clinical Oncology|2020Cited by 0